trial

Examining Risk Factors for Atypical Antipsychotic Metabolic Side Effects

NCTId NCT00815854
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 88 (actual)
Sponsored by University of Michigan
Primary completion 2019-05
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
88 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2008-10
Primary completion
2019-05
Eligibility
ALL · 18 Years · 90 Years

Interventions & indications

Drugs
Folic Acid

Sponsors

University of MichiganLead Sponsor
National Institute of Mental Health (NIMH)Collaborator

Investigators

1
Vicki L. Ellingrod, PharmDPrincipal Investigator

Sites

1 total
Ann Arbor, United States

Facts & assertions

4 sourced
Enrollment
88
Phase
NA
Primary Completion Date
2019-05
Status
COMPLETED
relationships
The graph out of here
drug
Folic Acid
drug
lead_sponsor
University of Michigan
company
collaborator
National Institute of Mental Health (NIMH)
company
indication
Schizophrenia
indication
Schizophrenia
indication
Insulin Resistance
indication
investigator
Vicki L. Ellingrod, PharmD
person